莱克酮 | 866594-60-7

• 物质功能分类: 有机原料 - 酮类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃类
• 中文名称: 莱克酮
• 中文别名: (3AS,4S,6AR)-四氢-4-甲氧基-呋喃并[3,4-B]呋喃-2(3H)-酮；(3aS,4S,6aR)-四氢-4-甲氧基-呋喃并(3,4-b)呋喃-2(3H)-酮；(3aS,4S,6aR)-四氢-4-甲氧基-呋喃并[3,4-b]呋喃-2(3H)-酮
• 英文名称: (3aS,4S,6aR)-4-methoxy-tetrahydro-furo[3.4-b]furan-2(3H)-one
• 英文别名: (3aS,4S,6aR)-4-methoxy-tetrahydro-furo[3,4-b]furan-2(3H)-one；(3aS,4S,6aR)-4-Methoxytetrahydrofuro[3,4-b]furan-2(3H)-one；(3aS,4S,6aR)-4-methoxy-3a,4,6,6a-tetrahydro-3H-furo[2,3-c]furan-2-one
• CAS: 866594-60-7
• 化学式: C₇H₁₀O₄
• 分子量: 158.154
• InChiKey: LQEIOPTZKCKTPQ-VPLCAKHXSA-N

物化性质

• 熔点：
  126-128℃ (isopropanol )
• 沸点：
  311.6±42.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  莱克酮 在 lithium aluminium tetrahydride 、 盐酸 作用下， 以 乙醚 、 甲醇 、 二氯甲烷 为溶剂， 反应 1.0h， 以45%的产率得到(3R,3AS,6AR)-六氢呋喃并[2,3-B]呋喃-3-醇
  参考文献：
  名称：

  [EN] METHODS FOR MAKING DARUNAVIR P2-LIGAND PRECURSORS
  [FR] PROCÉDÉS DE FABRICATION DE PRÉCURSEURS DE LIGAND P2 DARUNAVIR

  摘要：

  一种制备光学活性P2配体前体的方法，包括将D-木糖或其衍生物或D-葡萄糖或其衍生物转化为光学活性P2配体前体。

  公开号：

  WO2022035499A1
• 作为产物：
  描述：

  ethyl (E)-3-[(R)-2,2-dimethyl-1,3-dioxolan-4-yl]acrylate 在 甲醇 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 甲醇 为溶剂， 反应 21.0h， 生成 莱克酮
  参考文献：
  名称：

  Stereoselective and Efficient Synthesis of (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-ol

  摘要：

  [GRAPHICS]Two short and efficient synthesis routes have been developed for bis-THF-alcohol 2, a key building block of the investigational HIV protease inhibitor TMC114 (1). Using S-2,3-O-isopropylideneglyceraldehyde (4) as the source of chirality, both routes are based on a diastereoselective Michael addition of nitromethane to give predominantly the syn congeners 6 followed by a Nef oxidation and cyclization to afford lactone acetals 8, which are reduced and cyclized to give 2.

  DOI：

  10.1021/ol052554i

文献信息

• [EN] METHODS FOR THE PREPARATION OF (3R,3aS,6aR) HEXAHYDRO-FURO[2,3-b]FURAN-3-OL<br/>[FR] PROCEDES DE PREPARATION DE (3R,3AS,6AR)HEXAHYDRO-FURO[2,3-B]FURAN-3-OL
  申请人：TIBOTEC PHARM LTD

  公开号：WO2005095410A1

  公开（公告）日：2005-10-13

  The present invention relates to methods for the preparation of diastereomerically pure (3R,3aS,6aR) hexahydro-furo[2,3-b]furan-3-ol (6) as well as a novel intermediate, (3aR,4S,6aS) 4-methoxy-tetrahydro-furo[3,4-b]furan-2-one (4) for use in said methods. More in particular the invention relates to a stereoselective method for the preparation of diastereomerically pure (3R,3aS,6aR) hexahydro-furo[2,3-b]furan-3-ol, as well as methods for the crystallization of (3aR,4S,6aS) 4-methoxy-tetrahydro-furo[3,4-b]furan- 2-one and for the epimerization of (3aR,4R,6aS) 4-methoxy-tetrahydro-furo[3,4-b]-furan-2-one to (3aR,4S,6aS) 4-methoxy-tetrahydro-furo[3,4-b]furan-2-one.

  本发明涉及制备对映异构体纯度高的(3R,3aS,6aR)六氢呋喃[2,3-b]呋喃-3-醇（6）的方法，以及用于该方法的新型中间体(3aR,4S,6aS) 4-甲氧基四氢呋喃[3,4-b]呋喃-2-酮（4）。更具体地说，本发明涉及一种立体选择性的制备对映异构体纯度高的(3R,3aS,6aR)六氢呋喃[2,3-b]呋喃-3-醇的方法，以及用于(3aR,4S,6aS) 4-甲氧基四氢呋喃[3,4-b]呋喃-2-酮的结晶方法和(3aR,4R,6aS) 4-甲氧基四氢呋喃[3,4-b]-呋喃-2-酮的外消旋化为(3aR,4S,6aS) 4-甲氧基四氢呋喃[3,4-b]呋喃-2-酮的方法。
• [EN] METHOD FOR THE SYNTHESIS OF 4-ALKOXY-, 4-HYDROXY- AND 4-ARYLOXY-SUBSTITUTED TETRAHYDRO-FURO[3,4-B]FURAN-2(3H)-ONE COMPOUNDS<br/>[FR] PROCÉDÉ DE SYNTHÈSE DE COMPOSÉS DE TÉTRAHYDRO-FURO[3,4-B]FURAN-2(3H)-ONE SUBSTITUÉS 4-ALKOXY-, 4-HYDROXY- AND 4-ARYLOXY
  申请人：DSM IP ASSETS BV

  公开号：WO2009030733A1

  公开（公告）日：2009-03-12

  The present invention relates to a method for the synthesis of enantiomerically and diastereomerically enriched 4-alkoxy-, 4-hydroxy- or 4-aryloxy- substituted tetrahydro-furo[3,4-b]furan-2(3H)-ones by aldol coupling of a suitable hydroxyl-protected hydroxy-acetaldehyde and 4-oxobutanoic acid or an ester thereof, and subsequent removal of the protecting group from the aldol compound and (optionally simultaneous) cyclizations and acetal formation under acidic conditions in the presence of an alcohol, followed by optional isolation of the desired compounds. The invention also relates to compounds according to formulae [Xl] and [XII].

  本发明涉及一种通过适当的羟基保护羟基乙醛和4-氧代丁酸或其酯的醛缩合，以及随后去除醛缩合物中的保护基并在酸性条件下进行（可选同时进行）环化和缩醛形成的方法，从而合成对映体和对映体富集的4-烷氧基、4-羟基或4-芳氧基取代的四氢呋喃并[3,4-b]呋喃-2(3H)-酮，随后可选择地分离所需的化合物。该发明还涉及符合[XI]和[XII]式的化合物。
• METHODS FOR THE PREPARATION OF (3R,3aS,6aR) HEXAHYDRO-FURO[2,3-b]FURAN-3-OL
  申请人：Quaedflieg Mario Peter Jan Leonard

  公开号：US20070208184A1

  公开（公告）日：2007-09-06

  The present invention relates to methods for the preparation of diastereomerically pure (3R,3aS,6aR)hexahydro-furo[2,3-b]furan-3-ol as well as a novel intermediate, (3aR,4S,6aS)4-methoxy-tetrahydro-furo[3,4-b]furan-2-one for use in said methods. More in particular the invention relates to a stereoselective method for the preparation of diastereomerically pure (3R,3aS,6aR)hexahydro-furo[2,3-b]furan-3-ol, as well as methods for the crystallization of (3aR,4S,6aS)4-methoxy-tetrahydro-furo[3,4-b]furan-2-one and for the epimerization of (3aR,4R,6aS)4-methoxy-tetrahydro-furo[3,4-b]-furan-2-one to (3aR,4S,6aS)4-methoxy-tetrahydro-furo[3,4-b]furan-2-one.

  本发明涉及制备对映异构体纯度高的(3R,3aS,6aR)六氢呋喃[2,3-b]呋喃-3-醇的方法，以及一种新的中间体(3aR,4S,6aS)4-甲氧基四氢呋喃[3,4-b]呋喃-2-酮，用于上述方法。更具体地说，本发明涉及一种立体选择性方法，用于制备对映异构体纯度高的(3R,3aS,6aR)六氢呋喃[2,3-b]呋喃-3-醇，以及用于结晶(3aR,4S,6aS)4-甲氧基四氢呋喃[3,4-b]呋喃-2-酮和对(3aR,4R,6aS)4-甲氧基四氢呋喃[3,4-b]呋喃-2-酮进行外消旋反应以得到(3aR,4S,6aS)4-甲氧基四氢呋喃[3,4-b]呋喃-2-酮的方法。
• De Novo Synthesis of Conjugates
  申请人：Riggs-Sauthier Jennifer

  公开号：US20100184989A1

  公开（公告）日：2010-07-22

  The invention provides methods for the preparation of small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer obtained from a water-soluble oligomer composition. Such drugs are produced through modification of a synthetic pathway to attach the oligomer to an intermediate compound followed by completion of the synthetic path.

  本发明提供了一种制备化学修饰的小分子药物的方法，其中化学修饰是通过共价连接来自水溶性寡聚物组合物的水溶性寡聚物进行的。这种药物是通过修改合成途径将寡聚物连接到中间化合物，然后完成合成途径而生产的。
• Oligomer-Protease Inhibitor Conjugates
  申请人：Riggs-Sauthier Jennifer

  公开号：US20110269677A1

  公开（公告）日：2011-11-03

  The invention provides protease inhibitors that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the protease inhibitors not attached to the water-soluble oligomer.

  该发明提供了通过共价连接水溶性寡聚体进行化学修饰的蛋白酶抑制剂。该发明的结合物在通过任何一种给药途径进行给药时，表现出与未连接水溶性寡聚体的蛋白酶抑制剂不同的特性。